Abstract:ABSTRACTAttenuatedSalmonella entericaserovar Typhimurium has been used for targeted delivery of recombinant antigens to gut- and nose-associated lymphoid tissues. Contradictory reports have described the effect of preexisting immunity to the antigen delivery vehicle. We decided to examine this discrepancy by studying the effect of immunizing mice by the intranasal (i.n.) route withSalmonellaexpressing an insoluble protein and to study the ability to augment recall responses by boosting with eitherSalmonella-expressed protein or purified soluble protein alone. The glucan-binding domain (GLU) of the enzyme glucosyltransferase (GTF), which is an important virulence factor ofStreptococcus mutans, was recombinantly expressed in the insoluble phase inS. entericaserovar Typhimurium, and the immunogenicity of this construct was studied in mice. We examined the induction of primary immune responses by insoluble GLU polypeptide delivered inSalmonellaat week 1 (groups 1 and 2) and recall responses after a week 15 boost with eitherSalmonellaexpressing GLU (group 1) or purified GLU polypeptide (groups 2 and 3). Group 4 served as the control and received phosphate-buffered saline alone by the i.n. route. Significant anti-GLU serum immunoglobulin G (IgG) levels were seen in groups 1, 2, and 3 at week 18 (P< 0.001), i.e., 3 weeks after the booster immunization. Mice in group 2, who receivedSalmonellafollowed by GLU, had the highest GLU-specific IgG levels among all groups. The serum IgG levels persisted in all responding groups for at least 7 weeks after the boost (week 22). The IgG2a/IgG1 subclass ratio of serum anti-GLU antibodies in group 1 significantly increased after the boost. These results support the induction of a type 1-like immune response to GLU after primary and booster immunizations withSalmonellaexpressing GLU. On the other hand, group 2 mice, which receivedSalmonellaexpressing GLU as the primary dose and soluble protein as the booster dose, exhibited a shift from a type 1-like to a more type 2-like immune response to GLU following the boost. These results indicate thatS. entericaserovar Typhimurium is an excellent delivery vehicle for the insoluble and recombinantly expressed GLU of GTF and that this construct was especially effective in priming the host for a secondary response to soluble GLU polypeptide.

Immunogenicity of Salmonella Vector Vaccines Expressing SBR of Streptococcus Mutans under the Control of a T7-nirB (dual) Promoter System

Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine

Contribution of a Streptococcus mutans antigen expressed by a Salmonella vector vaccine in dendritic cell activation

Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus

Effect of Attenuated Salmonella Enterica Serovar Typhimurium Expressing A Streptococcus Mutans Antigen on Secondary Responses to the Cloned Protein

Two Novel Salmonella Bivalent Vaccines Confer Dual Protection against Two Salmonella Serovars in Mice

Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen

Oral immunization of mice and swine with an attenuated Salmonella choleraesuis [delta cya-12 delta(crp-cdt)19] mutant containing a recombinant plasmid

Regulated Delayed Shigella flexneri 2a O-antigen Synthesis in Live Recombinant Salmonella enterica Serovar Typhimurium Induces Comparable Levels of Protective Immune Responses with Constitutive Antigen Synthesis System.

Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses

Reversible Synthesis of Colanic Acid and O-antigen Polysaccharides in Salmonella Typhimurium Enhances Induction of Cross-Immune Responses and Provides Protection Against Heterologous Salmonella Challenge.

Novel Bacterial Delivery System with Attenuated Salmonella Typhimurium Carrying Plasmid Encoding Mtb Antigen 85A for Mucosal Immunization: Establishment of Proof of Principle in TB Mouse Model.

Immunization With a Combination of Four Recombinant Brucella abortus Proteins Omp16, Omp19, Omp28, and L7/L12 Induces T Helper 1 Immune Response Against Virulent B. abortus 544 Infection in BALB/c Mice

An oral recombinant Salmonella enterica serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice

Enhanced Immunogenicity of a Genetic Chimeric Protein Consisting of Two Virulence Antigens of Streptococcus Mutans and Protection Against Infection.

Evaluation of Efficacy, Biodistribution and Safety of Antibiotic-Free Plasmid Encoding Somatostatin Genes Delivered by Attenuated Salmonella Enterica Serovar Choleraesuis

Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity

[Construction, Safety and Immunogenicity Analysis of Attenuated Salmonella Typhimurium Harbouring TGEV DNA Vaccine].

Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit

Immunogenicity and cross-protective efficacy induced by delayed attenuated Salmonella with regulated length of lipopolysaccharide in mice

Type IVB Pilus Operon Promoter Controlling Expression of the Severe Acute Respiratory Syndrome-Associated Coronavirus Nucleocapsid Gene in Salmonella Enterica Serovar Typhi Elicits Full Immune Response by Intranasal Vaccination.